{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:48:21Z","timestamp":1790923701444,"version":"4.1.0"},"reference-count":11,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2009]]},"abstract":"<i>Background:<\/i> The impact of adjuvant chemotherapy on hepatic function and portal hypertension in patients with stages II\u2013III colon cancer has not been previously described. We conducted a retrospective study to assess the effects of adjuvant FOLFOX chemotherapy on the splenic index (SI) as a surrogate marker for portal hypertension. <i>Methods:<\/i> Stage II\u2013IIIcolorectal cancer patients treated with adjuvant FOLFOX or fluorouracil\/leucovorin (5-FU\/LV) at Roswell Park Cancer Institute between2002 and 2006were identified. Computerizedtomography (CT) scans obtained prior to and at completion of chemotherapy, and every 6 months thereafter were reviewed. Splenic size was evaluated using the SI (SI = length \u00d7 width \u00d7 height of the spleen). <i>Results:<\/i> 40 patientswere identified in the FOLFOX group and 23 in the 5-FU\/LV group. After 6 months of adjuvant chemotherapy, the mean increase in SI was 45.7 and 16.3% in the FOLFOX and 5-FU\/LV groups, respectively (p = 0.0069). SI increased by >100% in 6 patients (15%) in the FOLFOX group versus none in the 5-FU\/LV group (p = 0.16). The mean SI at completion of adjuvant chemotherapy was significantly higher in the FOLFOX group than in the 5-FU\/LV group (p = 0.007). The mean SI decreased steadily over a period of 2 years after discontinuation of FOLFOX, suggesting potential reversibility of oxaliplatin-induced hepatic injury in this setting. <i>Conclusions:<\/i> Adjuvant FOLFOX significantly increases the SI in patients with resected colorectal cancer in comparison to adjuvant 5-FU\/LV. The increase in SI may be a marker of oxaliplatin-induced hepatic injury and should be investigated further in prospective longitudinal studies of oxaliplatin-based adjuvant chemotherapy.<\/jats:p>","DOI":"10.1159\/000210025","type":"journal-article","created":{"date-parts":[[2009,3,25]],"date-time":"2009-03-25T14:41:06Z","timestamp":1237992066000},"page":"363-368","source":"Crossref","is-referenced-by-count":42,"title":["Adjuvant FOLFOX Chemotherapy and Splenomegaly in Patients with Stages II\u2013III Colorectal Cancer"],"prefix":"10.1159","volume":"76","author":[{"given":"Revathi","family":"Angitapalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna R.G.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiad","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Mashtare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory E.","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan G.","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2009,3,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2004.09.046"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa032709"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2006.08.2974"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2808%2960455-9"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2006.10.4380"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2005.05.3074"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2006.05.8156"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdh095"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097%2FSLA.0b013e31815774de"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11605-007-0149-4"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097%2F00004728-200009000-00022"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/210025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/210025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T22:46:40Z","timestamp":1745448400000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000210025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":11,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000210025","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}